Skip to main content

Advertisement

SpringerLink
Log in

Comparison of dual-color in-situ hybridization and fluorescence in-situ hybridization in HER2 gene amplification in breast cancer

  • Original Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

Background

HER2 is a prognostic factor in breast cancer, and is predictive of the effects of HER2-targeted drugs. HER2 tests are essential in invasive and metastatic breast cancer. Dual-color in-situ hybridization (DISH) is a novel genetic test, and we investigated its utility in HER2 testing in breast cancer.

Methods

Using DISH and two FISH methods (FISH method 1, FISH method 2) with representative slices of surgical specimens from 134 invasive breast cancer patients, we performed HER2 gene testing and compared the results for HER2 gene/CEP17 signal ratio and HER2 gene diagnosis.

Results

Of 134 patients, either the HER2 gene or the CEP17 signal could not be counted in 2 patients by DISH, in 1 patient by FISH method 1, and in 1 patient by FISH method 2. HER2 gene/CEP17 signal ratios were strongly correlated in DISH and FISH method 1 (R = 0.85, P < 0.05). Agreement of DISH and FISH method 1 for HER2 gene diagnosis was 98.5 % for all patients, irrespective of gene amplification (κ = 0.97). HER2 gene/CEP17 signal ratios were strongly correlated in DISH and FISH method 2 (R = 0.87, P < 0.05). Agreement of DISH and FISH method 2 for HER2 gene diagnosis was 94.1 % for gene amplification patients, 98.4 % for gene non-amplification patients, and 96.2 % for all patients (κ = 0.92).

Conclusions

DISH is useful for HER2 gene testing in breast cancer, and is recommended as a new option for assessing HER2 status.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–82.

    Article  CAS  PubMed  Google Scholar 

  2. Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist. 2003;8:307–25.

    Article  CAS  PubMed  Google Scholar 

  3. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17(9):2639–48.

    CAS  PubMed  Google Scholar 

  4. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25(1):118–45.

    Article  CAS  PubMed  Google Scholar 

  5. Hicks DG, Kulkarni S. HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools. Am J Clin Pathol. 2008;129(2):236–73.

    Article  Google Scholar 

  6. Carbone A, Botti G, Gloghini A, Semone G, Truini M, Curcio MP, et al. Delineation of HER2 gene status in breast carcinoma by silver in-situ hybridization is reproducible among laboratories and pathologists. J Mol Diagn. 2008;10(6):527–36.

    Article  PubMed Central  PubMed  Google Scholar 

  7. Isola J, Tanner M, Forsyth A, Cooke TG, Watters AD, Bartlett JM. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in-situ hybridization. Clin Cancer Res. 2004;10(14):4793–8.

    Article  CAS  PubMed  Google Scholar 

  8. Saez A, Andreu FJ, Segui MA, Bare ML, Fernandes S, Dinares C, et al. HER-2 gene amplification by chromogenic in-situ hybridization (CISH) compared with fluorescence in-situ hybridization (FISH) in breast cancer—a study of two hundred cases. Breast. 2006;15(4):519–27.

    Article  CAS  PubMed  Google Scholar 

  9. Nitta H, Hauss-Wegrzyniak B, Lehrkamp M, Murillo AE, Gaire F, Farrell M, et al. Development of automated brightfield double in-situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in-situ hybridization (FISH). Diagn Pathol. 2008;3:41.

    Article  PubMed Central  PubMed  Google Scholar 

  10. Garcia-Caballero T, Grabau D, Green AR, Gregory J, Schad A, Kohlwes E, et al. Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in-situ hybridization is comparable to fluorescence in-situ hybridization: a European multicentre study involving 168 specimens. Histopathology. 2010;56(4):472–80.

    Article  PubMed Central  PubMed  Google Scholar 

  11. Kato N, Itoh H, Serizawa A, Hatanaka Y, Umemura S, Osamura RY. Evaluation of HER2 gene amplification in invasive breast cancer using a dual-color chromogenic in-situ hybridization (dual CISH). Pathol Int. 2010;60(7):510–5.

    Article  PubMed  Google Scholar 

  12. Mayr D, Heim S, Weyrauch K, Zeindl-Eberhart E, Kunz A, Engel J, et al. Chromogenic in-situ hybridization for Her-2/neu-oncogene in breast cancer: comparison of a new dual-colour chromogenic in-situ hybridization with immunohistochemistry and fluorescence in-situ hybridization. Histopathology. 2009;55(6):716–23.

    Article  PubMed  Google Scholar 

  13. Bartlett JM, Campbell FM, Ibrahim M, O’Grady A, Faulkes C, Collins N, et al. A UK NEQAS ISH multicenter ring study using the Ventana HER2 dual-color ISH assay. Am J Clin Pathol. 2011;135(1):157–62.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported in part by Roche Diagnostics K.K. (Tokyo, Japan).

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Division of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan

    Rie Horii

  2. Bioinformatics Group, Genome Center, and Division of Cancer Genomics, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan

    Masaaki Matsuura

  3. Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan

    Takuji Iwase & Yoshinori Ito

  4. Division of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan

    Futoshi Akiyama

Authors
  1. Rie Horii
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masaaki Matsuura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takuji Iwase
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yoshinori Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Futoshi Akiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rie Horii.

About this article

Cite this article

Horii, R., Matsuura, M., Iwase, T. et al. Comparison of dual-color in-situ hybridization and fluorescence in-situ hybridization in HER2 gene amplification in breast cancer. Breast Cancer 21, 598–604 (2014). https://doi.org/10.1007/s12282-012-0436-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12282-012-0436-0

Keywords

Search

Navigation